Integra LifeSciences (NASDAQ:IART) Given New $25.00 Price Target at Truist Financial

Integra LifeSciences (NASDAQ:IART) had its target price reduced by equities researchers at Truist Financial from $37.00 to $25.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s target price would indicate a potential upside of 0.36% from the stock’s current price.

A number of other research firms also recently issued reports on IART. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Bank of America dropped their price objective on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a report on Tuesday. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $45.00 to $25.00 in a report on Tuesday. Oppenheimer lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $36.80.

Integra LifeSciences Trading Down 0.7 %

Shares of IART opened at $24.91 on Tuesday. Integra LifeSciences has a fifty-two week low of $22.36 and a fifty-two week high of $50.78. The company has a market capitalization of $1.96 billion, a PE ratio of 30.01, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The stock has a fifty day moving average of $32.67 and a two-hundred day moving average of $38.15. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same period in the prior year, the firm posted $0.74 earnings per share. The business’s quarterly revenue was down 3.2% compared to the same quarter last year. As a group, analysts forecast that Integra LifeSciences will post 3.19 EPS for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System increased its position in Integra LifeSciences by 18.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 81,614 shares of the life sciences company’s stock worth $2,893,000 after buying an additional 12,777 shares during the period. Russell Investments Group Ltd. grew its position in Integra LifeSciences by 8.0% in the 1st quarter. Russell Investments Group Ltd. now owns 50,502 shares of the life sciences company’s stock worth $1,790,000 after purchasing an additional 3,743 shares during the last quarter. Headlands Technologies LLC raised its holdings in shares of Integra LifeSciences by 54.3% during the first quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company’s stock valued at $169,000 after buying an additional 1,677 shares during the last quarter. Inspire Investing LLC boosted its position in shares of Integra LifeSciences by 14.8% during the first quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company’s stock worth $360,000 after buying an additional 1,311 shares during the period. Finally, Concurrent Investment Advisors LLC increased its position in Integra LifeSciences by 17.3% in the 1st quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company’s stock valued at $601,000 after acquiring an additional 2,500 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.